Glenmark Pharma

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE935A01035
  • NSEID: GLENMARK
  • BSEID: 532296
INR
2,155.60
-17.6 (-0.81%)
BSENSE

Jun 15, 03:30 PM

BSE+NSE Vol: 6.56 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Cr
Consolidate Quarterly Results
Mar'26
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Net Sales
3,770.59
3,900.62
6,046.87
3,264.44
3,256.20
3,387.55
3,433.80
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
3,770.59
3,900.62
6,046.87
3,264.44
3,256.20
3,387.55
3,433.80
Raw Material Cost
731.20
775.30
722.50
732.47
794.78
746.37
774.36
Purchase of Finished goods
446.29
748.56
620.45
581.34
344.74
418.15
443.08
(Increase) / Decrease In Stocks
-5.21
-228.76
-78.44
-298.23
-50.57
-80.28
-147.36
Employee Cost
887.44
841.40
1,086.26
762.75
736.57
788.49
786.57
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Expenses
948.27
894.36
1,336.55
905.59
869.66
914.59
975.23
Total Expenditure (Excl Depreciation)
3,007.99
3,030.86
3,687.32
2,683.92
2,695.18
2,787.32
2,831.88
Operating Profit (PBDIT) excl Other Income
762.60
869.76
2,359.55
580.52
561.02
600.23
601.92
Other Income
189.08
44.47
200.63
26.44
11.69
31.13
39.42
Operating Profit (PBDIT)
951.68
914.23
2,560.18
606.96
572.71
631.36
641.34
Interest
42.60
41.43
66.46
58.23
66.71
52.29
48.48
Exceptional Items
-373.40
-184.34
-1,385.12
-323.23
-372.82
0.00
0.00
Gross Profit (PBDT)
535.68
688.46
1,108.60
225.50
133.18
579.07
592.86
Depreciation
147.91
154.45
141.20
129.93
125.21
122.74
120.28
Profit Before Tax
387.77
534.00
967.40
95.58
7.97
456.33
472.57
Tax
86.45
130.77
356.97
48.61
3.59
108.30
118.09
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
301.32
403.23
610.43
46.97
4.38
348.03
354.49
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
301.32
403.23
610.43
46.97
4.38
348.03
354.49
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
-0.10
0.02
0.08
0.10
-0.27
0.07
0.27
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
301.41
403.21
610.35
46.87
4.65
347.96
354.21
Equity Capital
28.22
28.22
28.22
28.22
28.22
28.22
28.22
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Earnings per share (EPS)
10.68
14.29
21.63
1.66
0.16
12.33
12.55
Diluted Earnings per share
10.68
14.28
21.62
1.66
0.16
12.33
12.55
Operating Profit Margin (Excl OI)
20.28%
22.37%
39.3%
18.98%
17.42%
18.18%
17.7%
Gross Profit Margin
14.25%
17.71%
18.47%
7.37%
4.14%
17.54%
17.43%
PAT Margin
8.01%
10.37%
10.17%
1.54%
0.14%
10.54%
10.42%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Mar 2026 is -3.33% vs -35.49% in Dec 2025

stock-summary

Consolidate Net Profit

QoQ Growth in quarter ended Mar 2026 is -25.25% vs -33.94% in Dec 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is -12.32% vs -63.14% in Dec 2025

stock-summary

Interest

QoQ Growth in quarter ended Mar 2026 is 2.82% vs -37.66% in Dec 2025

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025

Compare Quarterly Results Of Glenmark Pharma With
Markets Mojo
Figures in Cr
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
3,770.59
3,603.32
167.27
4.64%
Other Operating Income
0.00
0.00
0.00
Total Operating income
3,770.59
3,603.32
167.27
4.64%
Raw Material Cost
731.20
894.94
-163.74
-18.30%
Purchase of Finished goods
446.29
497.77
-51.48
-10.34%
(Increase) / Decrease In Stocks
-5.21
-144.84
139.63
96.40%
Employee Cost
887.44
712.10
175.34
24.62%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
948.27
1,125.96
-177.69
-15.78%
Total Expenditure (Excl Depreciation)
3,007.99
3,085.93
-77.94
-2.53%
Operating Profit (PBDIT) excl Other Income
762.60
517.39
245.21
47.39%
Other Income
189.08
200.07
-10.99
-5.49%
Operating Profit (PBDIT)
951.68
717.46
234.22
32.65%
Interest
42.60
53.88
-11.28
-20.94%
Exceptional Items
-373.40
-134.97
-238.43
-176.65%
Gross Profit (PBDT)
535.68
528.61
7.07
1.34%
Depreciation
147.91
105.76
42.15
39.85%
Profit Before Tax
387.77
422.85
-35.08
-8.30%
Tax
86.45
171.17
-84.72
-49.49%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
301.32
251.68
49.64
19.72%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
301.32
251.68
49.64
19.72%
Share in Profit of Associates
0.00
-0.57
0.57
100.00%
Minority Interest
-0.10
14.65
-14.75
-100.68%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
301.41
236.46
64.95
27.47%
Equity Capital
28.22
23.91
4.31
18.03%
Face Value
1.00
2.00
0.00
Reserves
0.00
0.00
0.00
Earnings per share (EPS)
10.68
19.78
-9.10
-46.01%
Diluted Earnings per share
10.68
19.77
-9.09
-45.98%
Operating Profit Margin (Excl OI)
20.28%
14.36%
0.00
5.92%
Gross Profit Margin
14.25%
14.67%
0.00
-0.42%
PAT Margin
8.01%
6.98%
0.00
1.03%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Quarterly - Net Sales
Net Sales 3,770.59 Cr
in Mar 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Mar 2026 is -3.33% vs -35.49% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 15.80% vs 6.31% in Mar 2025

Quarterly - Consolidate Net Profit
Consolidate Net Profit 301.41 Cr
in Mar 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Mar 2026 is -25.25% vs -33.94% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 6,381.94% vs 100.38% in Mar 2025

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 762.60 Cr
in Mar 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Mar 2026 is -12.32% vs -63.14% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 35.93% vs 11.24% in Mar 2025

Quarterly - Interest
Interest 42.60 Cr
in Mar 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Mar 2026 is 2.82% vs -37.66% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is -36.14% vs -55.10% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 20.28%
in Mar 2026

Figures in %
stock-summary

QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025